Jump to content

J. Keith Joung: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Line 6: Line 6:


==Career==
==Career==
Joung is most well known for his work in genome editing and has contributed to the development of designer nucleases through protein engineering and assays for off-target detection.<ref>https://www.nytimes.com/2009/12/29/health/research/29zinc.html</ref><ref>https://www.sciencedaily.com/releases/2014/12/141216154729.htm</ref><ref>https://www.genomeweb.com/gene-silencinggene-editing/crispr-researchers-develop-highly-sensitive-method-identification-target#.XH8ifqeZNZ1</ref> In the mid-2000s, Joung's research was focused on creating [[zinc finger nuclease]] tools for biological research and gene therapy.<ref>https://www.nytimes.com/2009/12/29/health/research/29zinc.html</ref> He was the leader and founder of the [[Zinc finger|Zinc Finger]] Consortium and co-authored a study on Oligomerized Pool Engineering (OPEN), a publicly available strategy for rapidly constructing multi-finger arrays.<ref name="zincfingers">{{cite web|url=http://www.zincfingers.org/consortium-members.htm|publisher=zincfingers.org|title=The Zinc Finger Consortium &#124; Consortium Members|accessdate=2016-11-19}}</ref><ref>{{Cite journal|last=Maeder|first=Morgan L.|last2=Thibodeau-Beganny|first2=Stacey|last3=Osiak|first3=Anna|last4=Wright|first4=David A.|last5=Anthony|first5=Reshma M.|last6=Eichtinger|first6=Magdalena|last7=Jiang|first7=Tao|last8=Foley|first8=Jonathan E.|last9=Winfrey|first9=Ronnie J.|date=2008-07-25|title=Rapid "open-source" engineering of customized zinc-finger nucleases for highly efficient gene modification|journal=Molecular Cell|volume=31|issue=2|pages=294–301|doi=10.1016/j.molcel.2008.06.016|issn=1097-2765|pmc=2535758|pmid=18657511}}</ref>
Joung is most well known for his work in [[genome editing]] and has contributed to the development of designer nucleases through protein engineering and assays for off-target detection.<ref>https://www.nytimes.com/2009/12/29/health/research/29zinc.html</ref><ref>https://www.sciencedaily.com/releases/2014/12/141216154729.htm</ref><ref>https://www.genomeweb.com/gene-silencinggene-editing/crispr-researchers-develop-highly-sensitive-method-identification-target#.XH8ifqeZNZ1</ref> In the mid-2000s, Joung's research was focused on creating [[zinc finger nuclease]] tools for biological research and gene therapy.<ref>https://www.nytimes.com/2009/12/29/health/research/29zinc.html</ref> He was the leader and founder of the [[Zinc finger|Zinc Finger]] Consortium and co-authored a study on Oligomerized Pool Engineering (OPEN), a publicly available strategy for rapidly constructing multi-finger arrays.<ref name="zincfingers">{{cite web|url=http://www.zincfingers.org/consortium-members.htm|publisher=zincfingers.org|title=The Zinc Finger Consortium &#124; Consortium Members|accessdate=2016-11-19}}</ref><ref>{{Cite journal|last=Maeder|first=Morgan L.|last2=Thibodeau-Beganny|first2=Stacey|last3=Osiak|first3=Anna|last4=Wright|first4=David A.|last5=Anthony|first5=Reshma M.|last6=Eichtinger|first6=Magdalena|last7=Jiang|first7=Tao|last8=Foley|first8=Jonathan E.|last9=Winfrey|first9=Ronnie J.|date=2008-07-25|title=Rapid "open-source" engineering of customized zinc-finger nucleases for highly efficient gene modification|journal=Molecular Cell|volume=31|issue=2|pages=294–301|doi=10.1016/j.molcel.2008.06.016|issn=1097-2765|pmc=2535758|pmid=18657511}}</ref>


More recently, Joung has contributed to the development of TAL effector, [[TALENs]], and the RNA-guided [[CRISPR/Cas9]] system. In addition to demonstrating the use of the CRISPR/Cas9 system ''in vivo'' through the zebrafish model,<ref>Hwang WY, Fu Y, Reyon D, Maeder ML, Tsai SQ, Sander JD, Peterson RT, Yeh JR*, Joung JK*. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol. 2013 Mar;31(3):227-9.</ref> Joung has pioneered the creation of tools such as GUIDE-seq and CIRCLE-seq to detect nuclease off-targets within the genome.<ref>Tsai, S.Q., et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol (2015)</ref><ref>{{Cite journal|last=Tsai|first=Shengdar Q.|last2=Nguyen|first2=Nhu T.|last3=Malagon-Lopez|first3=Jose|last4=Topkar|first4=Ved V.|last5=Aryee|first5=Martin J.|last6=Joung|first6=J. Keith|date=June 2017|title=CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets|url=https://www.nature.com/nmeth/journal/v14/n6/full/nmeth.4278.html|journal=Nature Methods|language=en|volume=14|issue=6|pages=607–614|doi=10.1038/nmeth.4278|issn=1548-7091}}</ref> In 2016, his group became one of the first to report engineered high-fidelity CRISPR-Cas9 nucleases (HF1) with no detectable off-target effects.<ref>{{Cite journal|last=Kleinstiver|first=Benjamin P.|last2=Pattanayak|first2=Vikram|last3=Prew|first3=Michelle S.|last4=Tsai|first4=Shengdar Q.|last5=Nguyen|first5=Nhu T.|last6=Zheng|first6=Zongli|last7=Joung|first7=J. Keith|date=2016-01-28|title=High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects|journal=Nature|volume=529|issue=7587|pages=490–495|doi=10.1038/nature16526|issn=1476-4687|pmc=4851738|pmid=26735016}}</ref>
More recently, Joung has contributed to the development of TAL effector, [[TALENs]], and the RNA-guided [[CRISPR/Cas9]] system. In addition to demonstrating the use of the CRISPR/Cas9 system ''in vivo'' through the zebrafish model,<ref>Hwang WY, Fu Y, Reyon D, Maeder ML, Tsai SQ, Sander JD, Peterson RT, Yeh JR*, Joung JK*. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol. 2013 Mar;31(3):227-9.</ref> Joung has pioneered the creation of tools such as GUIDE-seq and CIRCLE-seq to detect nuclease off-targets within the genome.<ref>Tsai, S.Q., et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol (2015)</ref><ref>{{Cite journal|last=Tsai|first=Shengdar Q.|last2=Nguyen|first2=Nhu T.|last3=Malagon-Lopez|first3=Jose|last4=Topkar|first4=Ved V.|last5=Aryee|first5=Martin J.|last6=Joung|first6=J. Keith|date=June 2017|title=CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets|url=https://www.nature.com/nmeth/journal/v14/n6/full/nmeth.4278.html|journal=Nature Methods|language=en|volume=14|issue=6|pages=607–614|doi=10.1038/nmeth.4278|issn=1548-7091}}</ref> In 2016, his group became one of the first to report engineered high-fidelity CRISPR-Cas9 nucleases (HF1) with no detectable off-target effects.<ref>{{Cite journal|last=Kleinstiver|first=Benjamin P.|last2=Pattanayak|first2=Vikram|last3=Prew|first3=Michelle S.|last4=Tsai|first4=Shengdar Q.|last5=Nguyen|first5=Nhu T.|last6=Zheng|first6=Zongli|last7=Joung|first7=J. Keith|date=2016-01-28|title=High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects|journal=Nature|volume=529|issue=7587|pages=490–495|doi=10.1038/nature16526|issn=1476-4687|pmc=4851738|pmid=26735016}}</ref>

Revision as of 02:03, 6 March 2019

J. Keith Joung is an American pathologist and molecular biologist who is a Professor of Pathology at Harvard Medical School and the Desmond and Ann Heathwood Research Scholar at Massachusetts General Hospital.[1] He is a leading figure in the field of genome editing and has pioneered the development of designer nucleases and sensitive off-target detection methods.[2]

Education

In 1987, Joung graduated from Harvard College with a bachelor's degree in Biochemical Sciences.[3] He received an M.D. from Harvard Medical School and a Ph.D. in Genetics from Harvard University.[4]

Career

Joung is most well known for his work in genome editing and has contributed to the development of designer nucleases through protein engineering and assays for off-target detection.[5][6][7] In the mid-2000s, Joung's research was focused on creating zinc finger nuclease tools for biological research and gene therapy.[8] He was the leader and founder of the Zinc Finger Consortium and co-authored a study on Oligomerized Pool Engineering (OPEN), a publicly available strategy for rapidly constructing multi-finger arrays.[9][10]

More recently, Joung has contributed to the development of TAL effector, TALENs, and the RNA-guided CRISPR/Cas9 system. In addition to demonstrating the use of the CRISPR/Cas9 system in vivo through the zebrafish model,[11] Joung has pioneered the creation of tools such as GUIDE-seq and CIRCLE-seq to detect nuclease off-targets within the genome.[12][13] In 2016, his group became one of the first to report engineered high-fidelity CRISPR-Cas9 nucleases (HF1) with no detectable off-target effects.[14]

Joung is also one of the scientific co-founders of Editas Medicine, along with Jennifer Doudna, Feng Zhang, George Church, and David Liu.[15]

References

  1. ^ "Joung Laboratory - Massachusetts General Hospital, Boston, MA". massgeneral.org. Retrieved 2016-11-19.
  2. ^ https://www.pnas.org/content/113/18/4884
  3. ^ https://www.asgct.org/about/board-officers/j-keith-joung-md-phd
  4. ^ https://ccib.mgh.harvard.edu/joung#research
  5. ^ https://www.nytimes.com/2009/12/29/health/research/29zinc.html
  6. ^ https://www.sciencedaily.com/releases/2014/12/141216154729.htm
  7. ^ https://www.genomeweb.com/gene-silencinggene-editing/crispr-researchers-develop-highly-sensitive-method-identification-target#.XH8ifqeZNZ1
  8. ^ https://www.nytimes.com/2009/12/29/health/research/29zinc.html
  9. ^ "The Zinc Finger Consortium | Consortium Members". zincfingers.org. Retrieved 2016-11-19.
  10. ^ Maeder, Morgan L.; Thibodeau-Beganny, Stacey; Osiak, Anna; Wright, David A.; Anthony, Reshma M.; Eichtinger, Magdalena; Jiang, Tao; Foley, Jonathan E.; Winfrey, Ronnie J. (2008-07-25). "Rapid "open-source" engineering of customized zinc-finger nucleases for highly efficient gene modification". Molecular Cell. 31 (2): 294–301. doi:10.1016/j.molcel.2008.06.016. ISSN 1097-2765. PMC 2535758. PMID 18657511.
  11. ^ Hwang WY, Fu Y, Reyon D, Maeder ML, Tsai SQ, Sander JD, Peterson RT, Yeh JR*, Joung JK*. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol. 2013 Mar;31(3):227-9.
  12. ^ Tsai, S.Q., et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol (2015)
  13. ^ Tsai, Shengdar Q.; Nguyen, Nhu T.; Malagon-Lopez, Jose; Topkar, Ved V.; Aryee, Martin J.; Joung, J. Keith (June 2017). "CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets". Nature Methods. 14 (6): 607–614. doi:10.1038/nmeth.4278. ISSN 1548-7091.
  14. ^ Kleinstiver, Benjamin P.; Pattanayak, Vikram; Prew, Michelle S.; Tsai, Shengdar Q.; Nguyen, Nhu T.; Zheng, Zongli; Joung, J. Keith (2016-01-28). "High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects". Nature. 529 (7587): 490–495. doi:10.1038/nature16526. ISSN 1476-4687. PMC 4851738. PMID 26735016.
  15. ^ https://mcgovern.mit.edu/2013/11/25/editas-medicine-to-develop-new-class-of-genome-editing-therapeutics/
Retrieved from "https://en.wikipedia.org/w/index.php?title=J._Keith_Joung&oldid=886403167"